Publications by authors named "Frederik Cleeren"

Claim this Profile
C
cGMP-compliant high-yield automated production of [F]AlF-FAPI-74: optimization of quality control and evaluation of molar dose impact.
Ward Storms, Sofie Celen, Justine Maes, Kim Serdons, Karolien Goffin, Frederik Cleeren

EJNMMI Radiopharm Chem· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical characterization of 3p-C-DEPA and 3p-C-DEPA-PEG as potential Actinium-225 bifunctional chelators using DOTA and macropa as benchmarks.
Jessica Pougoue Ketchemen, Stephen Ahenkorah, Emmanuel Nwangele, Siphelele Siphesihle Pearl Malaza, Maarten Ooms, Frederik Cleeren

EJNMMI Radiopharm Chem· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted alpha therapy of ovarian cancer with Pb-labeled anti-PTK7 antibody: On-site Pb production and preclinical insights.
Yani Berckmans, Roxanne Wouters, Zeljka Raskovic-Lovre, Sara Van Mechelen, Kim Lindland, Frederik Cleeren

Nucl Med Biol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of FAPI PET/CT in cancer of unknown primary (CUP): A systematic review.
Justine Maes, Frederik Cleeren, Karolien Goffin, Jeroen Dekervel, Philippe Nafteux

Eur J Radiol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
Jun Toyohara, Philipp H Elsinga, Sergio Todde, Xiang-Guo Li, Silvio Aime, Frederik Cleeren

EJNMMI Radiopharm Chem· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Experience with Targeted Alpha-Emitter Peptide Receptor Radionuclide Therapy (α-PRRT) for Somatostatin Receptor-Positive Neuroendocrine Tumors.
Hannes Leupe, Merel Cauwenbergh, Frederik Cleeren, Jeroen Dekervel, Chris Verslype

Pharmaceuticals (Basel)· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of inter- and intraobserver agreement between [F]AlF-NOTA-octreotide and [Ga]Ga-DOTA-SSA PET/CT.
Hannes Leupe, Niloefar Ahmadi Bidakhvidi, Karolien Goffin, Bliede Van den Broeck, Sander Jentjens, Frederik Cleeren

EJNMMI Rep· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective PET imaging of CXCR4 using the AlF-labeled antagonist LY2510924.
Muriel Aline Spahn, Tom Van Loy, Sofie Celen, Michel Koole, Christophe M Deroose, Frederik Cleeren

Eur J Nucl Med Mol Imaging· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indium-111-Labeled Single-Domain Antibody for CXCR4 Imaging Using Single-Photon Emission Computed Tomography.
Muriel Aline Spahn, Stephanie Mareike Anbuhl, Kaat Luyten, Tom Van Loy, Matti F Pronker, Frederik Cleeren

Bioconjug Chem· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitochondria-tropic radioconjugates to enhance the therapeutic potential of terbium-161.
Joana F Santos, Camille Van Laere, Catarina D Silva, Irwin Cassells, Célia Fernandes, Frederik Cleeren

EJNMMI Radiopharm Chem· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increasing brain half-life of antibodies by additional binding to myelin oligodendrocyte glycoprotein, a CNS specific protein.
Marie-Lynn Cuypers, Tom Jaspers, Jarne Clerckx, Simon Leekens, Christopher Cawthorne, Frederik Cleeren

Fluids Barriers CNS· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
Peter Jh Scott, Ivan Penuelas, Ana Rey, Silvio Aime, Pillai M R Ambikalmajan, Frederik Cleeren

EJNMMI Radiopharm Chem· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical impact of using [F]AlF-NOTA-octreotide PET/CT instead of [Ga]Ga-DOTA-SSA PET/CT: Secondary endpoint analysis of a multicenter, prospective trial.
Hannes Leupe, Elin Pauwels, Timon Vandamme, Bliede Van den Broeck, Willem Lybaert, Frederik Cleeren

J Neuroendocrinol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of [Ga]Ga-DOTA-AeK as a Potential Imaging Tool for PET Imaging of Cell Wall Synthesis in Bacterial Infections.
Palesa C Koatale, Mick M Welling, Sipho Mdanda, Amanda Mdlophane, John Takyi-Williams, Frederik Cleeren

Pharmaceuticals (Basel)· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of [Cu]Cu-trastuzumab as a theranostic against HER2-positive breast cancer.
Jessica Pougoue Ketchemen, Fabrice Ngoh Njotu, Hanan Babeker, Stephen Ahenkorah, Anjong Florence Tikum, Frederik Cleeren

Eur J Nucl Med Mol Imaging· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy?
Janke Kleynhans, Thomas Ebenhan, Frederik Cleeren, Mike Machaba Sathekge

Eur J Nucl Med Mol Imaging· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Second generation AlF-labeled D-amino acid peptide for CXCR4 targeted molecular imaging.
Muriel Aline Spahn, Kaat Luyten, Tom Van Loy, Mike Sathekge, Christophe M Deroose, Frederik Cleeren

Nucl Med Biol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside.
Camille Van Laere, Michel Koole, Christophe M Deroose, Michiel Van de Voorde, Kristof Baete, Frederik Cleeren

Theranostics· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and Preclinical Evaluation of PSMA-Targeted In-Radioconjugates Containing a Mitochondria-Tropic Triphenylphosphonium Carrier.
Joana F Santos, Maria T Braz, Paula Raposinho, Frederik Cleeren, Irwin Cassells

Mol Pharm· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiopharmaceuticals for Cancer Imaging and Therapy.
Guy Bormans, Frederik Cleeren

Pharmaceutics· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
F-Labeled Somatostatin Analogs as PET Tracers for the Somatostatin Receptor: Ready for Clinical Use.
Hannes Leupe, Stephen Ahenkorah, Jeroen Dekervel, Marcus Unterrainer, Eric Van Cutsem, Frederik Cleeren

J Nucl Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prospective comparison of [F]AlF-NOTA-octreotide PET/MRI to [Ga]Ga-DOTATATE PET/CT in neuroendocrine tumor patients.
Lennert Boeckxstaens, Elin Pauwels, Vincent Vandecaveye, Wies Deckers, Frederik Cleeren

EJNMMI Res· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiochemical and Biological Evaluation of 3p--NETA-ePSMA-16, a Promising PSMA-Targeting Agent for Radiotheranostics.
Erika Murce, Stephen Ahenkorah, Savanne Beekman, Maryana Handula, Debra Stuurman, Frederik Cleeren

Pharmaceuticals (Basel)· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct comparison of [F]AlF-NOTA-JR11 and [F]AlF-NOTA-octreotide for PET imaging of neuroendocrine tumors: Antagonist versus agonist.
Stephen Ahenkorah, Christopher Cawthorne, Erika Murce, Christophe M Deroose, Thomas Cardinaels, Frederik Cleeren

Nucl Med Biol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highlight selection of radiochemistry and radiopharmacy developments by editorial board.
Oliver C Kiss, Peter J H Scott, Martin Behe, Ivan Penuelas, Jan Passchier, Frederik Cleeren

EJNMMI Radiopharm Chem· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis